Based in Singapore, Glenda brings with her over 10 years of experience in building, growing and driving animal health businesses across the Asia-Pacific region.
“The focus on curbing antibiotics usage is the main growth driver in APAC and Chr. Hansen has a long standing presence in key Asian probiotic markets where legislation and/or consumer preferences favor the use of probiotics in animal health.
The presence or risk of developing antibiotic resistance has led governments across Asia to increase the speed of reducing usage of antibiotics growth promoters (AGPs) at the same time as consumer demands from export and domestic markets are putting more focus on premium protein products. We are aiming for business growth in countries like China and Vietnam where we witness an increasing interest for science based probiotics. Glenda will play a key role for Chr. Hansen in meeting these ambitions in the APAC region,” says SVP Vilson Simon, Animal Health.
“Having been in the animal nutrition industry for over 10 years, I am passionate about providing the best solutions for the industry to help them meet the regulatory requirements in safety and efficacy while optimizing their output.I am excited to join Chr. Hansen, a leader in natural solutions for food, health and agriculture. I look forward to working with the Chr. Hansen team in APAC to drive the growth of probiotics and silage inoculants that will help the industry be more productive and sustainable,” says Glenda Leong, APAC Sales Director, Animal Health.
Prior to joining Chr. Hansen, Glenda held leadership positions in AB Vista Singapore and Provimi Singapore.
Chr. Hansen continues to bring innovative Animal Health solutions to the Asia Pacific markets where we experience an increasing awareness of the benefits of natural probiotics to secure healthy animals and efficient feed utilization.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 3,000 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com